Drug intelligence / Profile preview

ClindaCare

Development stage: Unknown
Lead developer: Brisk Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical

Overview

**ClindaCare** is a Brisk Pharmaceuticals dental co-pack containing clindamycin hydrochloride 150 mg, ibuprofen 800 mg, and chlorhexidine gluconate 0.12%. It combines an oral lincosamide antibacterial for susceptible dental or oral bacterial infections, an oral nonsteroidal anti-inflammatory drug for pain and inflammation, and a topical oral antiseptic rinse for reduction of oral microbial burden during dental recovery. The product is a convenience pack of established active ingredients rather than a novel molecular entity.

Brand names: ClindaCare

Targets

PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on ClindaCare.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ClindaCare.

Explore the full profile